Treatment Outcomes of Diabetic Patients With Erectile Dysfunction Prescribed High-Dose Tadalafil
Abstract
Objective: To assess the treatment outcome of diabetic patients with erectile dysfunction who are prescribed an alternate daily high dose of tadalafil over a 120-day treatment period. Methods: This was a single-site, retrospective, observational study of 63 diabetic men with erectile dysfunction prescribed an alternate daily dose of 30mg of tadalafil between January 1, 2021, and December 31, 2021. Treatment outcomes accessed medication compliance, adverse drug reactions, and patient treatment satisfaction at 60- and 120-days treatment. Results: Mean age of patients was 58.3 years and included patients who suffered from comorbidities ranging from hypertension (54.0%), dyslipidemia (52.3%), and depression (9.5%). At 60 days in the study, 69.8% were satisfied and continued the treatment. However, at the end of the 120-treatment period, a low number of men (17.5%) were satisfied with the treatment and therefore did not remain on the treatment protocol. These patients reported a lack of medication dose efficacy (86.5%), non-compliance with treatment as prescribed (65.4%), and adverse drug reactions (30.8%) as reasons for discontinuing treatment. None of the identified patient demographics were significantly associated with 120-day continuous treatment. Similarly, the odds ratio derived from the logistic regression did not demonstrate an association between the selected variables and the outcome of 120-day continuous treatment retention. Conclusion: This retrospective case series…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 63 participants or records.
Read the paper
Related studies
- Antioxidant efficacy and the upregulation of Nrf2-mediated HO-1 expression by (+)-lariciresinol, a lignan isolated from Rubia philippinensis, through the activation of p38
- Anti-influenza virus activity of green tea by-products in vitro and efficacy against influenza virus infection in chickens
- Therapeutic Potential of Mesenchymal Stem Cells (MSCs) and MSC-Derived Extracellular Vesicles for the Treatment of Spinal Cord Injury
- The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model
- Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer
- In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.